// PROTOCOLS / longevity
▶ Longevity protocol
Longevity pages distinguish between measured healthspan practices, biomarker claims, public critiques, and low-confidence aspirational claims such as immortality by 2039.
Daily inputs, long-range targets, and explicit avoidances are separated into the same terminal panels as the BJ.WATCH reference. Source-aware summary only.
idxtimehabit
01 nightHBT Prioritize measured healthspan basics: exercise, sleep regularity, nutrition, risk-factor monitoring, and clinician-guided prevention.
concepts/biomarker-driven-longevity-protocols.md 02 dailyHBT Read biological-age and speed-of-aging numbers as tracked claims with source trails and critique links nearby.
raw/articles/bryan-johnson/years-biomarkers-limits-2026-04-20.md Long-term objectives
target 01 Treat Johnson’s November 2026 music-longevity relay as an attributed research relay with an exactly verified trial count and a category upgrade the paper does not support. “Music is a longevity therapy / > lowers heart rate / > lowers blood pressure / > lowers cortisol / > lowers anxiety and restlessness / Protocol: a song you love. / 104 randomized trials / 9,617 people” traces to de Witte, Spruit, van Hooren, Moonen, Stams, “Effects of music interventions on stress-related outcomes: a systematic review and two meta-analyses,” Health Psychology Review, June 2020;14(2):294-324 (10.1080/17437199.2019.1627897; PubMed 31167611): two multilevel meta-analyses of exactly 104 RCTs and exactly 9,617 participants, with all four claimed benefits mapping onto measured outcomes — heart rate d = .456, stress-hormone levels d = .349, blood pressure d = .343, anxiety/restlessness-type psychological outcomes d = .545 (overall physiological d = .380, psychological d = .545). Boundaries: the paper measures stress reduction, not longevity — no included trial tracked mortality, disease, or aging endpoints; the pooled effects are small-to-medium and heterogeneous; the evidence base is mostly short-term, often single-session; “lowers cortisol” narrows the broader hormone outcome class; the post names no study. Not evidence that listening to music extends life, a reader listening protocol, or medical advice.https://x.com/bryan_johnson/status/2116962664572477809
target 02 Treat Johnson’s October 2026 aging-economics relay as a real three-week-old modeling paper whose money figure the post both inflates and converts into cash-sounding dollars. “Slowing aging after the age 50 can add 3.6 yrs of life and is worth $4 million in economic value” traces to Felizzi, “Economic impact of biomarker-based aging interventions on healthcare costs and individual value,” Frontiers in Genetics, October 11, 2026 (10.3389/fgene.2026.1814599) — a single-author Hypothesis & Theory simulation by an enGene (Basel) industry author chaining DunedinPACE (via Mak et al. 2023 frailty coupling, 10.1093/gerona/glad251) to Swiss-calibrated survival, frailty, and cost data. The lifespan figure is a round-up: the most optimistic scenario (CR2, pace of aging assumed held at 1.0) yields 3.58 years, the moderate scenario 2.89. The money figure drifts twice: the paper’s most optimistic total individual value is CHF 3,236,195 (≈$3.5–3.6M, so “$4 million” overstates it by about a tenth), and it is a willingness-to-pay construct — CHF 1,216,186 survival plus CHF 2,020,009 health quality, undiscounted, in the Murphy–Topel/Scott value-of-life framework (Scott, Ellison & Sinclair, Nature Aging 2021, 10.1038/s43587-021-00080-0) — a welfare measure, not cash or savings; modeled healthcare-system savings are CHF 131,608 per person over 40 years, and the healthcare case turns cost-sensitive once CHF 600 twice-yearly DunedinPACE testing is included. Boundaries: CR2’s hold-at-1.0 assumption is not demonstrated by any available intervention; DunedinPACE captures one methylation axis of aging by the paper’s own caveat; costs and life tables are Swiss; the author frames the work around consumer longevity-medicine business models. Not evidence that any available intervention adds 3.6 years of life, a wealth or savings figure, or medical advice.https://x.com/bryan_johnson/status/2115443720145223923
target 03 Treat Johnson’s October 2026 bone-pressure lifespan post as an attributed research claim that self-corrected the same day — the “+80 days (+9.4%)” figure now traces to a real paper, but the paper is mice, and its loading is a machine. Johnson’s October 24 follow-up (“Here is the correct paper for the stats in the original post”) identifies Bai et al., “Dynamic force sensing by bone delays aging and extends lifespan,” Cell Metabolism, published online October 23, 2026 (10.1016/j.cmet.2026.09.020): dynamic tibial axial loading (2 N at 2 Hz, 300 cycles, twice weekly) in mice at 20–24 months extended median lifespan 9.4%/79.5 days, reversed bone-marrow immunosenescence, reduced liver steatosis, and improved cognition and endurance, covering the post’s brain/liver/immune triad; the correction’s PGE2 mechanism sentence traces to the same group’s Cx43-hemichannel work (Zhao et al., eLife 2022, 10.7554/eLife.74365). Boundaries: one mouse study published one day before the post; the loader is an external calibrated device compressing an anesthetized tibia, not jumping; the “human equivalent of 7–9 yrs” is arithmetic on the mouse percentage; no human loading evidence exists. Not evidence that jumping or dunk training extends life, a reader exercise prescription, or medical advice.https://x.com/bryan_johnson/status/2113992318206497133
target 04 Read Johnson’s October 2026 IL-11 lifespan relay as a verified paper carried with a drifted figure. The work is real and landmark: Widjaja et al., “Inhibition of IL-11 signalling extends mammalian healthspan and lifespan,” Nature, July 17, 2024 (10.1038/s41586-024-07701-9) — anti-IL-11 antibody from 75 weeks until death extended median mouse lifespan 22.5% in males and 25% in females, with fewer tumours at autopsy, and Boehringer Ingelheim’s Phase IIa IPF trial of BI 765423 (announced January 13, 2026) makes the “Phase II human clinical trials for lung fibrosis” leg real. But the relay’s “35% in female mice” misquotes the paper (25%) and Johnson’s own July 17, 2024 post, which quoted both figures correctly — the same transcription-drift class as the bone-pressure figure two days earlier. Boundaries: mouse antibody dosing and knockout genetics; no human longevity data; the IPF trial tests lung function, not aging endpoints. Not evidence for anti-IL-11 in humans, a drug expectancy, or medical advice.https://x.com/bryan_johnson/status/2114834793296978182
target 05 Treat Johnson’s October 2026 psilocybin-Parkinson’s relay as a real three-day-old letter with every design limitation dropped. The study verifies: Bradley, Kelley, et al., JAMA Psychiatry research letter, published October 21, 2026 (10.1001/jamapsychiatry.2026.2733) — banked blood from 9 of 12 participants in the UCSF open-label pilot (NCT04932434), five inflammatory markers still significantly below baseline a month after the final 25-mg dose, GDF15 improving right after dosing then losing the gain at follow-up. The relay’s “In 9 Parkinson’s patients” hides that this is an uncontrolled, unblinded subsample of a 12-person safety pilot whose authors say the signal needs controlled confirmation; inflammatory markers move with sleep, stress, infection, and lifting depression; co-author disclosures include psychedelic-industry ties. Not evidence psilocybin treats Parkinson’s, a psychedelic-use endorsement, or medical advice.https://x.com/bryan_johnson/status/2114361011474215200
target 06 Separate durable healthspan practices from frontier enhancement, drug-stack, gene-therapy, and immortality narratives.concepts/biomarker-driven-longevity-protocols.md
target 07 Treat Johnson’s October 2026 “Resting heart is the new thirst trap” post as an attributed ideology-and-marketing disclosure, not health guidance. The mortality predictor verifies: the CMAJ 2016 meta-analysis of 46 cohorts (10.1503/cmaj.150535; 1,246,203 adults, 78,349 deaths) found each 10 bpm higher resting heart rate at all-cause mortality RR 1.09 (95% CI 1.07–1.12) and RHR >80 bpm at RR 1.45, with publication bias and no guideline endorsement. The self-reported 207-post/366,220-like/78.3M-view campaign metrics, the RHR-41 “perfect night sleep” promise, and “I promise every part of your life will improve” are marketing claims, not evidence; a predictor of mortality is not proof that a routine lowers risk. Not a sleep protocol, a health directive, or medical advice.https://x.com/bryan_johnson/status/2111149094576202049
target 08 Treat Johnson’s October 2026 “I can’t find a way to use my genome” post as an attributed negative-result admission, not a verdict on genome sequencing. The prevalence context verifies: the deCODE study of 57,933 Icelanders (NEJM, 10.1056/NEJMoa2300792) found 4.0% carry an actionable ACMG SF v3.0 genotype (~96% carry none), Korea’s national pilot found 3.75% of 7,472 genomes, Qatar’s program found 3.5%, and WA HCA’s 2024 WGS review reported ACMG-actionable findings in 0–12.5% of tested persons with very-low certainty of management change. The $7,902 matched 30x long-read + 100x short-read resequencing is a program claim; one null result does not cover carrier screening, pharmacogenomics, or diagnostic contexts. Not a testing recommendation for or against sequencing, or medical advice.https://x.com/bryan_johnson/status/2110438813122359731
target 09 Treat Johnson’s October 2026 “The Blue Zones are an illusion” post as an attributed amplification of a contested debunking, not a settled demographic finding. The underlying records verify: Japan’s 2010 audit found 82% of listed centenarians deceased (~230,000 people), Italy’s 1997 pension audit found ~30,000 dead “living” recipients, Costa Rica’s 2008 review found 42% of alleged centenarians had misstated ages, and Newman’s Ig Nobel-winning work documents age-records problems across Blue Zone regions. But the critique (Saul Justin Newman, non-peer-reviewed preprint) is disputed by working demographers and gerontologists — Sardinia’s Blue Zone researchers defend their validated records, and independent evidence for activity, moderate intake, and social connection stands regardless of the hotspot claims. Not a settled finding that no population exhibits exceptional longevity, a dietary directive, or medical advice.https://x.com/bryan_johnson/status/2110155459781112084
target 10 Treat Johnson’s September 2026 semaglutide mouse-lifespan post as an attributed research summary, not a longevity signal for humans. The study is real (Feng et al., Nature, 10.1038/s41586-026-10940-7: 20-month-old female C57BL/6 mice, median lifespan 742→834 days, endurance/memory/glucose gains, calorie-restriction-matched control), but it is one strain, female-only, mouse-only, median lifespan—and Johnson’s Immortals Rx sells GLP-1 medications, making the amplification commercially adjacent. Not human evidence, medication guidance, or medical advice.https://x.com/bryan_johnson/status/2100746261964202305
target 11 Treat the September 2026 organ-aging schedule post as an attributed research summary. The figures match PathStAR (bioRxiv 2025.09.29.679316; Nature Aging: 25,306 postmortem GTEx biopsies, 970 donors aged 21–70, 40 tissues, 30.3M image patches, age-blind training) and describe population-level tissue-architecture schedules—early vascular aging in the 30s, late uterus/vagina aging in the 50s, biphasic ovary and digestive/male-reproductive tissues—not a personal organ-age test or clinical risk model.https://x.com/bryan_johnson/status/2097458211670589449
target 12 Treat the September 2026 Immortals Concierge pricing disclosure ($75,000 to $1,000,000 memberships) as a commercial milestone, not an efficacy signal. The service list (physician, coach, 200+ biomarker panel, whole-body MRI) is a concrete disclosure; the “world-exclusive” immune cryopreservation and iPSC age-reversal claims are not evidence of established clinical services, and the efficacy argument is Johnson’s own testimonial biomarkers.https://x.com/bryan_johnson/status/2098148080025846005
target 13 Treat the September 2026 Eight Sleep biological-age model as a commercial measurement claim with a real but unreviewed preprint behind it. The post’s figures track BCG-FM (Kjaer et al., arXiv:2606.07692: 2.04M hours / 136,575 participants; 3.26-year MAE; diabetes 0.852, heart failure 0.822, hypertension 0.810, sleep apnea 0.792 AUROC), but the product is a membership feature co-developed with Johnson’s Immortals, its internal disease labels are self-reported, and it is not a diagnostic device by the post’s own words. Not a validated longevity measurement, a purchasing signal, or medical advice.https://x.com/bryan_johnson/status/2095675388810936586
target 14 Classify daily Tadalafil/Cialis and similar drug claims as hypothesis-generating prescription-intervention claims unless independent clinical evidence supports the exact longevity use case.raw/articles/bryan-johnson/x-twitter-daily-2026-06-13.md
target 15 Classify Immortals Rx GLP-1, SGLT2, peptide, and NAD+ listings as commercial platform expansion; do not treat off-label longevity positioning as proven outcome evidence.raw/articles/bryan-johnson/x-twitter-daily-2026-06-23.md
target 16 Classify the July 2026 six-option GLP-1 catalog as a more specific commercial listing, not validation of weight-loss or longevity efficacy, compounded-treatment safety, prescribing criteria, formulation status, or availability.raw/articles/bryan-johnson/x-twitter-daily-2026-07-23.md
target 17 Classify Johnson’s August 2026 Viagra-plus-statins cancer-spread post as a low-confidence, product-adjacent intervention claim. The post itself labels the study preclinical and human evidence observational, and its extension from sildenafil to tadalafil is not established treatment evidence.raw/articles/bryan-johnson/x-twitter-daily-2026-08-04.md
target 18 Classify sauna/HSP27 claims as mechanistic biomarker self-experimentation unless replicated and tied to clinically meaningful outcomes.raw/articles/bryan-johnson/x-twitter-daily-2026-06-17.md
target 19 Classify the July 2026 sauna checklist as an attributed expansion from N=1 biomarker testing into public protocol guidance; its frequency, heat-dose, fertility, microplastics, recovery, hydration, and environmental claims require independent evidence and safety context.raw/articles/bryan-johnson/x-twitter-daily-2026-07-24.md
target 20 Classify the Midjourney scanner essay as a measurement-modality argument; structural imaging may complement chemical and functional data, but the third-party device and routine-screening claims need validation.raw/articles/bryan-johnson/x-twitter-daily-2026-06-24.md
target 21 Classify Johnson’s June 2026 wearable reply as a relative-tracking claim: consistency can help trend detection, but it does not settle absolute accuracy or clinical validity.raw/articles/bryan-johnson/x-twitter-daily-2026-06-25.md
target 22 Classify the inherited-cancer DNA + RNA panel as early-risk surveillance framing: useful for understanding Johnson’s measurement stack, not evidence that broad genetic screening improves outcomes for every reader.raw/articles/bryan-johnson/x-twitter-daily-2026-06-26.md
target 23 Classify the July 2026 single-cell immune sequencing thread as an AIG diagnostic/readout extension, not as proof that Johnson has a validated antigen-specific therapy.raw/articles/bryan-johnson/x-twitter-daily-2026-07-04.md
target 24 Classify the July 2026 low-ferritin / Monoferric follow-up as self-reported diagnostic follow-through and a false-negative argument, not as generalized iron-infusion guidance.raw/articles/bryan-johnson/x-twitter-daily-2026-07-08.md
target 25 Classify the July 2026 AIG cure roadmap as a staged, investigational personal experiment; the “Bryan in a dish” ex-vivo model and candidate precision therapies are not established clinical outcomes.raw/articles/bryan-johnson/x-twitter-daily-2026-07-09.md
target 26 Classify the July 2026 Kate Tolo endometriosis workup as a female-health measurement case study: complementary tests can expose false negatives, but Johnson’s case narrative is not a validated general protocol or medical advice.raw/articles/bryan-johnson/x-twitter-daily-2026-07-10.md
target 27 Classify the July 2026 1,900-biomarker / 14.8M-data-point Kate Tolo announcement as measurement-scale ambition. It is a planned N=1 collection program, not completed or independently validated female-health evidence.raw/articles/bryan-johnson/x-twitter-daily-2026-07-16.md
target 28 Classify Johnson’s July 2026 disease-resolution/frontier-biotech pivot as strategic positioning. The disease and proposed research program are unspecified, so the announcement is not evidence of a cure or protocol change readers can act on.raw/articles/bryan-johnson/x-twitter-daily-2026-07-21.md
target 29 Classify Johnson’s July 2026 autologous iPSC “clone” post as speculative regenerative-biotech positioning. It supplies no cell-line characterization, cited trial, organ, delivery method, safety evidence, or outcome and is not evidence of a human clone or available treatment.raw/articles/bryan-johnson/x-twitter-daily-2026-07-22.md
target 30 Classify Immortals’ July 2026 disease-resolution infrastructure expansion as strategic frontier-biotech positioning. Naming iPSCs, organoids, deep cellular characterization, and personalized therapy development does not establish a clinically available platform or evidence of diagnosis, treatment, safety, cure, or outcome.raw/articles/bryan-johnson/x-twitter-daily-2026-07-25.md
target 31 Classify the July 2026 operational Kate Tolo baseline as measurement-scale ambition and protocol operations. The 100-day N=1 plan is not completed or independently validated female-health evidence, and its sensitive-data methods and governance remain unpublished.raw/articles/bryan-johnson/x-twitter-daily-2026-07-26.md
target 32 Classify Johnson’s August 2026 brain-clearance post as an uncited, preclinical research lead. The source describes one intranasal gene therapy in mice but supplies no named paper, human evidence, translational safety data, Blueprint intervention, or clinical outcome.raw/articles/bryan-johnson/x-twitter-daily-2026-08-14.md
target 33 Classify Johnson’s August 2026 mRNA–Keytruda post as third-party research commentary. He describes a tumor-fingerprint mRNA therapy paired with Keytruda in a first Phase 3 trial but names no trial, paper, sponsor, or data, so it is not a Blueprint intervention, an available treatment, or medical advice.https://x.com/bryan_johnson/status/2090212567235149828
target 34 Keep the Immortals rename and immortality search-trend narrative in the ideology/brand lane; it does not increase confidence in the 2039 forecast.raw/articles/bryan-johnson/x-twitter-daily-2026-06-20.md
target 35 Keep the June 2026 immortality manifesto and “Die Economy” frame in the ideology/forecast lane unless independent evidence supports the specific biological and AI claims.raw/articles/bryan-johnson/x-twitter-daily-2026-06-25.md
target 36 Keep critiques visible so biomarker improvements do not become unsupported longevity promises.raw/articles/bryan-johnson/years-biomarkers-limits-2026-04-20.md
Forbidden
FORBID: Do not render “immortality by 2039” as a realistic forecast or medical endpoint.concepts/immortality-by-2039.md
FORBID: Do not collapse Johnson’s ideology, Blueprint marketing, and independent evidence into one confidence level.concepts/biomarker-driven-longevity-protocols.md